Indication Pipeline


Presbyopia is the inability to read up close caused by loss of elasticity of the natural lens with age.  It affects nearly everyone over the age of 40.  CXLens was designed to accurately correct presbyopia by reshaping the cornea to compensate for natural lens stiffness using its real-time closed loop Ultrasound dosing technology to achieve smooth center-distance multifocality on the cornea.  Presbyopia affects over 120 million Americans (2 billion globally) representing a $15B opportunity in the US.

Control of Progressive Pediatric Myopia

Myopia (nearsightedness) is a global public health crisis. By 2050, nearly 5 billion people or 1 out of every 2 people on earth will suffer from myopia. In the USA, myopia cases have increased 66% since 1971. Today in East and Southeast Asia in countries such as South Korea, Taiwan, Singapore, China and Japan the prevalence of myopia is 80-90% among urban teenagers. 

Looking forward, our comfortable, motion insensitive CXL will give TECLens the ability to treat young children with qCXL for control of myopia progression. The same center-distance corneal shape used for presbyopia can reduce the peripheral hyperopia that drives myopia progression while eliminating the underlying myopic error, potentially freeing millions of young patients from spectacle dependency and the risks of pathologic myopia.  Orthokeratology and biofocal contact lens are being used for this today, but these techniques require years of daily compliance to lens use and care which can be very challenging with young children.  We believe that CXL can offer a permanent one-time treatment to reduce in peripheral hyperopic defocus and stop kids from significant myopia progression.


Keratoconus (KCN) is a progressive eye disease in which the normally round cornea thins and begins to bulge into a cone-like shape. Progression of this disease can degrade vision to a point necessitating a corneal transplant in 1 out of 5 patients1.  Once thought to be an Orphan Disease in the US, Keratoconus is now known to affect 1:375 persons or about 650,000 people in the US, mostly bilaterally.  This is about a $3.5 market opportunity.  CXLens has been shown to arrest the progression of KCN. TECLens control console can drive two CXLens devices at once to treat both eyes simultaneously representing a 400% increase in clinical efficiency. No other CXL system can treat both eyes at once.